Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Ursodiol vs URSO Forte
NCT02385032Phase 1Completed
- Sponsor
- Daewoong Pharmaceutical
- Start
- Feb 2015
- Primary completion
- Mar 2015
- Modality
- Orthosteric Ligands
01
Overview
Phase 1, randomised, open-label trial of ursodeoxycholic acid in primary biliary cholangitis (PBC) (2 arms), sponsored by Daewoong Pharmaceutical. Primary endpoints: Area Under the Curve to the last measurable concentration at 72 hours and Maximum Plasma Concentration at 72 hours. Started Feb 2015; status: completed.
02
Drugs
ursodeoxycholic acid
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NCT02385032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02385032.